clinical trial · NCT07449754
Belvarafenib in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant Melanoma
Hanmi Pharmaceutical Company Limited·phase2·recruiting·n = 45
Advanced or Metastatic MelanomaBelvarafenibCobimetinib
brief summary
This is a Phase 2 open-label, multicenter, single-arm study evaluating the combination of Belvarafenib and Cobimetinib in patients with locally advanced or metastatic melanoma with NRAS mutations. The study plans to assess ORR, DCR, DOR, TTP, PFS, OS and safety of the participating subjects. Treatment cycles for all subjects will be 28 days in duration and Belvarafenib and Cobimetinib will be administered orally in combination.
started
Feb 12, 2026
primary completion
Sep 1, 2029
completion
Mar 1, 2030
last updated
Mar 4, 2026
official title
A Phase 2, Multicenter, Single-Arm Study of Belvarafenib (HM95573) in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant Melanoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol